A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy

Bibliography

• Jiang T, Huang Z, Lin Y, The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2012;59(4):850-60
   Web of Science ®Google Scholar
• Yoh K, Hirayama A, Ishizaki K, Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 2008;13(11):1159-70
   PubMed Web of Science ®Google Scholar
• Ungvari Z, Bailey-Downs L, Gautam T, Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia. Am J Physiol Heart Circ Physiol 2011;300(4):H1133-40
   Web of Science ®Google Scholar
• Xue M, Qian Q, Adaikalakoteswari A, Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008;57(10):2809-17
   PubMed Web of Science ®Google Scholar
• Zheng H, Whitman SA, Wu W, Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011;60(11):3055-66
   PubMed Web of Science ®Google Scholar
• Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 1995;49(2):57-68
   PubMed Web of Science ®Google Scholar
• Honda T, Rounds BV, Bore L, Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1999;9(24):3429-34
   PubMed Web of Science ®Google Scholar
• Honda T, Rounds BV, Gribble GW, Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998;8(19):2711-14
   PubMed Web of Science ®Google Scholar
• Honda T, Honda Y, Favaloro FG Jr, A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 2002;12(7):1027-30
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby K, Yore MM, Platforms and networks in triterpenoid pharmacology. Drug Dev Res 2007;68(4):174-82
   Web of Science ®Google Scholar
• Liby K, Hock T, Yore MM, The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005;65(11):4789-98
   PubMed Web of Science ®Google Scholar
• Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7(5):357-69
   PubMed Web of Science ®Google Scholar
• Hayes JD, McMahon M, Chowdhry S, Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 2010;13(11):1713-48
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Liby KT, Stephenson KK, Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005;102(12):4584-9
   PubMed Web of Science ®Google Scholar
• Honda T, Padegimas EM, David E, 2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent. Bioorg Med Chem Lett 2010;20(7):2275-8
   PubMed Web of Science ®Google Scholar
• Yang L, Calingasan NY, Thomas B, Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 2009;4(6):e5757
   PubMed Web of Science ®Google Scholar
• Tsao T, Kornblau S, Safe S, Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res 2010;70(12):4949-60
   PubMed Web of Science ®Google Scholar
• Speranza G, Gutierrez ME, Kummar S, Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors. Cancer Chemother Pharmacol 2012;69(2):431-8
   PubMed Web of Science ®Google Scholar
• Hong DS, Kurzrock R, Supko JG, Phase I Trial with a Novel Orally Administered Synthetic Triterpenoid RTA 402 (CDDO-Me) in Patients with Solid Tumors and Lymphoid Malignancies [abstract B82]. Proceedings of the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference; San Francisco, CA; 2007
   Google Scholar
• Osburn WO, Yates MS, Dolan PD, Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol Sci 2008;104(1):218-27
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Youn JI, Weber H, Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010;16(6):1812-23
   PubMed Web of Science ®Google Scholar
• Pergola PE, Krauth M, Huff JW, Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 2011;33(5):469-76
   PubMed Web of Science ®Google Scholar
• Saha PK, Reddy VT, Konopleva M, The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem 2010;285(52):40581-92
   PubMed Web of Science ®Google Scholar
• Shin S, Wakabayashi J, Yates MS, Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol 2009;620(1-3):138-44
   PubMed Web of Science ®Google Scholar
• Schwartz S, Denham D, Hurwitz C, Bardoxolone Methyl Shown to Improve Renal Function in Patients with Chronic Kidney Disease and Type 2 Diabetes. Mellitus American Society of Nephrology Annual Scientific Meeting; Morial Convention Center; New Orleans, LA, Room Louisiane; 2009
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414(6865):782-7
   PubMed Web of Science ®Google Scholar
• Pergola PE, Raskin P, Toto RD, Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365(4):327-36
   PubMed Web of Science ®Google Scholar
• Motola D, Piccinni C, Biagi C, Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf 2012;35(4):315-23
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170(14):1191-201
   PubMed Web of Science ®Google Scholar
• Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341(15):1127-33
   PubMed Web of Science ®Google Scholar
• U. S. Renal Data System. USRDS 2004 annual data report: atlas of end-stage renal disease in the United States.. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, USA: 2004
   Google Scholar
• Stephenson JM, Kenny S, Stevens LK, Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995;12(2):149-55
   PubMed Web of Science ®Google Scholar
• Adler AI, Stevens RJ, Manley SE, Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63(1):225-32
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813-20
   PubMed Web of Science ®Google Scholar
• Wu QQ, Wang Y, Senitko M, Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1. Am J Physiol Ren Physiol 2011;300(5):F1180-92
   PubMed Web of Science ®Google Scholar